JPWO2022204568A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022204568A5 JPWO2022204568A5 JP2023559015A JP2023559015A JPWO2022204568A5 JP WO2022204568 A5 JPWO2022204568 A5 JP WO2022204568A5 JP 2023559015 A JP2023559015 A JP 2023559015A JP 2023559015 A JP2023559015 A JP 2023559015A JP WO2022204568 A5 JPWO2022204568 A5 JP WO2022204568A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- domain
- chain comprises
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 185
- 239000000611 antibody drug conjugate Substances 0.000 claims description 111
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 111
- 230000035772 mutation Effects 0.000 claims description 41
- 239000000427 antigen Substances 0.000 claims description 21
- 102000036639 antigens Human genes 0.000 claims description 21
- 108091007433 antigens Proteins 0.000 claims description 21
- 239000012634 fragment Substances 0.000 claims description 21
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 claims description 19
- 239000003112 inhibitor Substances 0.000 claims description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- -1 6-maleimidocaproyl Chemical group 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 8
- 206010027476 Metastases Diseases 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 230000009401 metastasis Effects 0.000 claims description 7
- 206010039491 Sarcoma Diseases 0.000 claims description 6
- 210000002889 endothelial cell Anatomy 0.000 claims description 6
- BQWBEDSJTMWJAE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[(2-iodoacetyl)amino]benzoate Chemical compound C1=CC(NC(=O)CI)=CC=C1C(=O)ON1C(=O)CCC1=O BQWBEDSJTMWJAE-UHFFFAOYSA-N 0.000 claims description 5
- 235000018417 cysteine Nutrition 0.000 claims description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 210000003712 lysosome Anatomy 0.000 claims description 4
- 230000001868 lysosomic effect Effects 0.000 claims description 4
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 claims description 4
- PVBORIXVWRTHOZ-UHFFFAOYSA-N (2,5-dioxopyrrol-1-yl)methyl cyclohexanecarboxylate Chemical compound C1CCCCC1C(=O)OCN1C(=O)C=CC1=O PVBORIXVWRTHOZ-UHFFFAOYSA-N 0.000 claims description 3
- CTIFFJZCLXQJHT-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-cyclobutyl-4-pyridin-2-ylsulfanylbutanoate Chemical compound C1(CCC1)C(CCC(=O)ON1C(CCC1=O)=O)SC1=NC=CC=C1 CTIFFJZCLXQJHT-UHFFFAOYSA-N 0.000 claims description 3
- ZHCYUAYWLHQPTD-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-cyclohexyl-4-pyridin-2-ylsulfanylbutanoate Chemical compound C1(CCCCC1)C(CCC(=O)ON1C(CCC1=O)=O)SC1=NC=CC=C1 ZHCYUAYWLHQPTD-UHFFFAOYSA-N 0.000 claims description 3
- WEASHVXTHUPVLZ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-cyclopropyl-4-pyridin-2-ylsulfanylbutanoate Chemical compound C1(CC1)C(CCC(=O)ON1C(CCC1=O)=O)SC1=NC=CC=C1 WEASHVXTHUPVLZ-UHFFFAOYSA-N 0.000 claims description 3
- OWSHKQHZDSXYRH-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-pyridin-2-ylsulfanylhexanoate Chemical compound N1=C(C=CC=C1)SC(CCC(=O)ON1C(CCC1=O)=O)CC OWSHKQHZDSXYRH-UHFFFAOYSA-N 0.000 claims description 3
- ORKRNTKKXLJEOC-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 5-methyl-4-pyridin-2-ylsulfanylhexanoate Chemical compound CC(C(CCC(=O)ON1C(CCC1=O)=O)SC1=NC=CC=C1)C ORKRNTKKXLJEOC-UHFFFAOYSA-N 0.000 claims description 3
- AGGWFDNPHKLBBV-YUMQZZPRSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=O AGGWFDNPHKLBBV-YUMQZZPRSA-N 0.000 claims description 3
- AFZIRBOYYNKYFJ-UHFFFAOYSA-N 4-pyridin-2-ylsulfanylpentanoic acid Chemical compound OC(=O)CCC(C)SC1=CC=CC=N1 AFZIRBOYYNKYFJ-UHFFFAOYSA-N 0.000 claims description 3
- OMNVYXHOSHNURL-WPRPVWTQSA-N Ala-Phe Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OMNVYXHOSHNURL-WPRPVWTQSA-N 0.000 claims description 3
- LRBVHYGKNRIQPP-UHFFFAOYSA-N C1(CCCC1)C(CCC(=O)ON1C(CCC1=O)=O)SC1=NC=CC=C1 Chemical compound C1(CCCC1)C(CCC(=O)ON1C(CCC1=O)=O)SC1=NC=CC=C1 LRBVHYGKNRIQPP-UHFFFAOYSA-N 0.000 claims description 3
- UAKFFGIBVYYHAF-UHFFFAOYSA-N CC(C(CCC(=O)ON1C(CCC1=O)=O)SC1=NC=CC=C1)CC Chemical compound CC(C(CCC(=O)ON1C(CCC1=O)=O)SC1=NC=CC=C1)CC UAKFFGIBVYYHAF-UHFFFAOYSA-N 0.000 claims description 3
- HSRXSKHRSXRCFC-WDSKDSINSA-N Val-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(O)=O HSRXSKHRSXRCFC-WDSKDSINSA-N 0.000 claims description 3
- 108010011559 alanylphenylalanine Proteins 0.000 claims description 3
- 230000008614 cellular interaction Effects 0.000 claims description 3
- 229960002173 citrulline Drugs 0.000 claims description 3
- 230000003993 interaction Effects 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- MPHYKSLFRQXIQE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 5-ethyl-4-pyridin-2-ylsulfanylheptanoate Chemical compound C(C)C(C(CCC(=O)ON1C(CCC1=O)=O)SC1=NC=CC=C1)CC MPHYKSLFRQXIQE-UHFFFAOYSA-N 0.000 claims description 2
- 201000003076 Angiosarcoma Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000013210 hematogenous Diseases 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 230000001926 lymphatic effect Effects 0.000 claims description 2
- 230000002132 lysosomal effect Effects 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 210000000663 muscle cell Anatomy 0.000 claims description 2
- 230000005937 nuclear translocation Effects 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 claims 1
- 101000652736 Homo sapiens Transgelin Proteins 0.000 claims 1
- 102100031013 Transgelin Human genes 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 description 31
- 238000000034 method Methods 0.000 description 18
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 6
- 235000004279 alanine Nutrition 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 5
- GTBCXYYVWHFQRS-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)pentanoate Chemical compound C=1C=CC=NC=1SSC(C)CCC(=O)ON1C(=O)CCC1=O GTBCXYYVWHFQRS-UHFFFAOYSA-N 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000004308 thiabendazole Substances 0.000 description 3
- VRDGQQTWSGDXCU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-iodoacetate Chemical compound ICC(=O)ON1C(=O)CCC1=O VRDGQQTWSGDXCU-UHFFFAOYSA-N 0.000 description 2
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical group O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
- JSHOVKSMJRQOGY-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCSSC1=CC=CC=N1 JSHOVKSMJRQOGY-UHFFFAOYSA-N 0.000 description 2
- OWGOYNSFBOQRRO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-cyclobutyl-4-(pyridin-2-yldisulfanyl)butanoate Chemical compound C1(CCC1)C(CCC(=O)ON1C(CCC1=O)=O)SSC1=NC=CC=C1 OWGOYNSFBOQRRO-UHFFFAOYSA-N 0.000 description 2
- UTZTZUCTABINRD-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-cyclopropyl-4-(pyridin-2-yldisulfanyl)butanoate Chemical compound C1(CC1)C(CCC(=O)ON1C(CCC1=O)=O)SSC1=NC=CC=C1 UTZTZUCTABINRD-UHFFFAOYSA-N 0.000 description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- LQILVUYCDHSGEU-UHFFFAOYSA-N 4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexane-1-carboxylic acid Chemical compound C1CC(C(=O)O)CCC1CN1C(=O)C=CC1=O LQILVUYCDHSGEU-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229930126263 Maytansine Natural products 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000000732 arylene group Chemical group 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 125000002993 cycloalkylene group Chemical group 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000005549 heteroarylene group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- NFJWAGOKMMRHHY-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[[2-[[2-[[2-[4-(2,5-dioxopyrrol-1-yl)butanoylamino]acetyl]amino]acetyl]amino]acetyl]amino]propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCNC(=O)CNC(=O)CNC(=O)CNC(=O)CCCN1C(=O)C=CC1=O NFJWAGOKMMRHHY-UHFFFAOYSA-N 0.000 description 1
- RBVOVMPKOQOCFL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-cyclobutyl-3-(pyridin-2-yldisulfanyl)propanoate Chemical compound C1(CCC1)C(CC(=O)ON1C(CCC1=O)=O)SSC1=NC=CC=C1 RBVOVMPKOQOCFL-UHFFFAOYSA-N 0.000 description 1
- PAXQVFMIUZJDOC-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-cyclopropyl-3-(pyridin-2-yldisulfanyl)propanoate Chemical compound C1(CC1)C(CC(=O)ON1C(CCC1=O)=O)SSC1=NC=CC=C1 PAXQVFMIUZJDOC-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 description 1
- GWEVSJHKQHAKNW-UHFFFAOYSA-N 4-[[1-(2,5-dioxopyrrolidin-1-yl)-2h-pyridin-2-yl]disulfanyl]-2-sulfobutanoic acid Chemical compound OC(=O)C(S(O)(=O)=O)CCSSC1C=CC=CN1N1C(=O)CCC1=O GWEVSJHKQHAKNW-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004820 halides Chemical group 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163166793P | 2021-03-26 | 2021-03-26 | |
| US63/166,793 | 2021-03-26 | ||
| PCT/US2022/022041 WO2022204568A1 (en) | 2021-03-26 | 2022-03-25 | Maytansine-antibody conjugates and methods of using same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024511479A JP2024511479A (ja) | 2024-03-13 |
| JP2024511479A5 JP2024511479A5 (https=) | 2025-04-01 |
| JPWO2022204568A5 true JPWO2022204568A5 (https=) | 2025-04-01 |
Family
ID=83397950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023559015A Pending JP2024511479A (ja) | 2021-03-26 | 2022-03-25 | メイタンシン抗体コンジュゲートおよびそれを使用する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240156978A1 (https=) |
| EP (1) | EP4313009A4 (https=) |
| JP (1) | JP2024511479A (https=) |
| CN (1) | CN117412741A (https=) |
| AU (1) | AU2022245388A1 (https=) |
| CA (1) | CA3213065A1 (https=) |
| WO (1) | WO2022204568A1 (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015054427A1 (en) * | 2013-10-10 | 2015-04-16 | Beth Israel Deaconess Medical Center, Inc. | Tm4sf1 binding proteins and methods of using same |
| WO2015081282A1 (en) * | 2013-11-27 | 2015-06-04 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
| CN109265546B (zh) * | 2017-07-17 | 2022-05-24 | 同济大学苏州研究院 | 用于治疗癌症的新靶标 |
| MX2020002241A (es) * | 2017-08-28 | 2020-09-03 | Angiex Inc | Anticuerpos anti-tm4sf y métodos de uso de los mismos. |
| US12428477B2 (en) * | 2019-02-27 | 2025-09-30 | Angiex, Inc. | Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the same |
-
2022
- 2022-03-25 AU AU2022245388A patent/AU2022245388A1/en active Pending
- 2022-03-25 CN CN202280038264.9A patent/CN117412741A/zh active Pending
- 2022-03-25 EP EP22776761.3A patent/EP4313009A4/en active Pending
- 2022-03-25 WO PCT/US2022/022041 patent/WO2022204568A1/en not_active Ceased
- 2022-03-25 JP JP2023559015A patent/JP2024511479A/ja active Pending
- 2022-03-25 CA CA3213065A patent/CA3213065A1/en active Pending
-
2023
- 2023-09-25 US US18/473,517 patent/US20240156978A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7585230B2 (ja) | バイパラトピックＦＲ－α抗体及びイムノコンジュゲート | |
| JP7467610B2 (ja) | カンプトテシン誘導体及びその複合体 | |
| US11517625B2 (en) | Antibody-drug-conjugate and its use for the treatment of cancer | |
| JP6258523B2 (ja) | Ｉｇｆ−１ｒ抗体−薬物複合体および癌の処置のためのその使用 | |
| KR101125524B1 (ko) | 칼리치아미신 유도체-운반체 접합체 | |
| JP2017518304A (ja) | 抗体−薬物コンジュゲート、それらの製造、及びそれらの治療用途 | |
| RU2012112067A (ru) | Терапевтические dll4-связующие белки | |
| US20260042847A1 (en) | Cysteine engineered antibody constructs, conjugates and methods of use | |
| JP2019505520A (ja) | 抗体およびその薬物コンジュゲートの製剤 | |
| JP2025061007A5 (https=) | ||
| JPWO2022204568A5 (https=) | ||
| CA3248952A1 (en) | PHARMACEUTICAL COMPOSITION COMPRISING AN ANTI-CD79B ANTIBODY-DRUG CONJUGATE AND ITS USE | |
| JPWO2020176794A5 (https=) | ||
| JPWO2022078523A5 (https=) | ||
| RU2832083C2 (ru) | Бипаратопные fr-альфа антитела и иммуноконъюгаты | |
| RU2824761C2 (ru) | Биофармацевтические композиции и связанные с ними способы | |
| WO2023222108A1 (zh) | 抗体-药物偶联物的制备方法 | |
| JP2021517133A5 (https=) | ||
| RU2023100251A (ru) | Антитело против клаудина 18.2 и его конъюгат антитело-лекарственное средство | |
| WO2026035986A1 (en) | Humanized anti-cdh17 antibodies and use of the same | |
| WO2026069278A1 (en) | Anti-cd123 antibodies and neodegrader conjugates | |
| EA052782B1 (ru) | Конъюгаты антитело к тканевому фактору-лекарственное средство и связанные способы | |
| RU2023135796A (ru) | Биспецифическая связывающая молекула, которая связывается с vegf и ang2, и ее применение | |
| RU2021100667A (ru) | Иммуноконъюгаты, нацеленные на adam9, и способы их применения |